Targeted protein degradation: A promising approach for cancer treatment

Lundin, 2015, Oligonucleotide therapies: The past and the present, Hum. Gene Ther., 26, 475, 10.1089/hum.2015.070 Wittrup, 2015, Knocking down disease: A progress report on siRNA therapeutics, Nat. Rev. Genet., 16, 543, 10.1038/nrg3978 Fellmann, 2017, Cornerstones of CRISPR-Cas in drug discovery and therapy, Nat. Rev. Drug Discov., 16, 89, 10.1038/nrd.2016.238 Housman, 2014, Drug resistance in cancer: An overview, Cancers, 6, 1769, 10.3390/cancers6031769 Ottis, 2017, Proteolysis-targeting chimeras: Induced protein degradation as a therapeutic strategy, ACS Chem. Biol., 12, 892, 10.1021/acschembio.6b01068 Sakamoto, 2001, Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation, Proc. Natl. Acad. Sci. U. S. A., 98, 8554, 10.1073/pnas.141230798 Guo, 2019, Degrading proteins in animals: “PROTAC”tion goes in vivo, Cell Res, 29, 179, 10.1038/s41422-019-0144-9 Sakamoto, 2010, Protacs for treatment of cancer, Pediatr. Res., 67, 505, 10.1203/PDR.0b013e3181d35017 Neklesa, 2017, Targeted protein degradation by PROTACs, Pharmacol. Ther., 174, 138, 10.1016/j.pharmthera.2017.02.027 Cromm, 2017, The proteasome in modern drug discovery: Second life of a highly valuable drug target, ACS Cent. Sci., 3, 830, 10.1021/acscentsci.7b00252 Bard, 2018, Structure and function of the 26S proteasome, Annu. Rev. Biochem., 87, 697, 10.1146/annurev-biochem-062917-011931 Kleiger, 2014, Perilous journey: A tour of the ubiquitin-proteasome system, Trends Cell Biol, 24, 352, 10.1016/j.tcb.2013.12.003 Hipp, 2019, The proteostasis network and its decline in ageing, Nat. Rev. Mol. Cell Biol., 20, 421, 10.1038/s41580-019-0101-y Sun, 2020, PROTACs as potential therapeutic agents for cancer drug resistance, Biochemistry, 59, 240, 10.1021/acs.biochem.9b00848 Zhou, 2020, Chemoproteomic-driven discovery of covalent PROTACs, Biochemistry, 59, 128, 10.1021/acs.biochem.9b00795 Sakamoto, 2003, Development of protacs to target cancer-promoting proteins for ubiquitination and degradation, Mol. Cell. Proteom., 2, 1350, 10.1074/mcp.T300009-MCP200 Schwartz, 2009, Targeting proteins for destruction by the ubiquitin system: Implications for human pathobiology, Annu. Rev. Pharmacol. Toxicol., 49, 73, 10.1146/annurev.pharmtox.051208.165340 Olson, 2018, Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation, Nat. Chem. Biol., 14, 163, 10.1038/nchembio.2538 Sun, 2018, BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells, Leukemia, 32, 343, 10.1038/leu.2017.207 Saenz, 2017, Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells, Leukemia, 31, 1951, 10.1038/leu.2016.393 Tinworth, 2016, Small molecule-mediated protein knockdown as a new approach to drug discovery, Med. Chem. Commun., 7, 2206, 10.1039/C6MD00347H Fedorov, 2006, Off-target effects by siRNA can induce toxic phenotype, RNA, 12, 1188, 10.1261/rna.28106 Burnett, 2012, RNA-based therapeutics: Current progress and future prospects, Chem. Biol., 19, 60, 10.1016/j.chembiol.2011.12.008 Gosink, 1995, Redirecting the specificity of ubiquitination by modifying ubiquitin-conjugating enzymes, Proc. Natl. Acad. Sci. USA, 92, 9117, 10.1073/pnas.92.20.9117 Schneekloth, 2008, Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics, Bioorg. Med. Chem. Lett., 18, 5904, 10.1016/j.bmcl.2008.07.114 Buckley, 2012, Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α, Angew. Chem. Int. Ed., 51, 11463, 10.1002/anie.201206231 Buckley, 2012, Targeting the von hippel–lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction, J. Am. Chem. Soc., 134, 4465, 10.1021/ja209924v Su, 2019, Potent and preferential degradation of CDK6 via proteolysis targeting Chimera degraders, J. Med. Chem., 62, 7575, 10.1021/acs.jmedchem.9b00871 Robb, 2017, Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC), Chem. Commun., 53, 7577, 10.1039/C7CC03879H Schiedel, 2018, Chemically induced degradation of sirtuin 2 (Sirt2) by a proteolysis targeting Chimera (PROTAC) based on sirtuin rearranging ligands (SirReals), J. Med. Chem., 61, 482, 10.1021/acs.jmedchem.6b01872 Yang, 2019, Plasticity in designing PROTACs for selective and potent degradation of HDAC6, Chem. Commun., 55, 14848, 10.1039/C9CC08509B Zengerle, 2015, Selective small molecule induced degradation of the BET bromodomain protein BRD4, ACS Chem. Biol., 10, 1770, 10.1021/acschembio.5b00216 Wang, 2016, New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation, Biochem. Pharmacol., 116, 200, 10.1016/j.bcp.2016.07.017 Peng, 2019, Identification of new small-molecule inducers of estrogen-related receptor α (ERRα) degradation, ACS Med. Chem. Lett., 10, 767, 10.1021/acsmedchemlett.9b00025 Khan, 2022, Recent developments in the Medicinal Chemistry and therapeutic potential of anti-cancer Protacs based molecules, Curr. Med. Chem., 30, 1576, 10.2174/0929867329666220803112409 Bondeson, 2017, Targeted protein degradation by small molecules, Annu. Rev. Pharmacol. Toxicol., 57, 107, 10.1146/annurev-pharmtox-010715-103507 Gadd, 2017, Structural basis of PROTAC cooperative recognition for selective protein degradation, Nat. Chem. Biol., 13, 514, 10.1038/nchembio.2329 Montrose, 2014, Design of a PROTAC that antagonizes and destroys the cancer-forming X-protein of the hepatitis B virus, Biochem. Biophys. Res. Commun., 453, 735, 10.1016/j.bbrc.2014.10.006 Zhou, 2020, PROTAC: A promising technology for cancer treatment, Eur. J. Med. Chem., 203, 112539, 10.1016/j.ejmech.2020.112539 Rotin, 2009, Physiological functions of the HECT family of ubiquitin ligases, Nat. Rev. Mol. Cell Biol., 10, 398, 10.1038/nrm2690 Sakamoto, 2002, Ubiquitin-dependent proteolysis: Its role in human diseases and the design of therapeutic strategies, Mol. Genet. Metab., 77, 44, 10.1016/S1096-7192(02)00146-4 Handley, 1991, Molecular cloning, sequence, and tissue distribution of the human ubiquitin-activating enzyme E1, Proc. Natl. Acad. Sci. U. S. A., 88, 258, 10.1073/pnas.88.1.258 Nalepa, 2006, Drug discovery in the ubiquitin–proteasome system, Nat. Rev. Drug Discov., 5, 596, 10.1038/nrd2056 Moreau, 2020, Proteolysis-targeting chimeras in drug development: A safety perspective, Br. J. Pharmacol., 177, 1709, 10.1111/bph.15014 Li, 2022, Proteolysis-targeting chimeras (PROTACs) in cancer therapy, Mol. Cancer, 21, 1, 10.1186/s12943-021-01434-3 Zhou, 2018, Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression, J. Med. Chem., 61, 462, 10.1021/acs.jmedchem.6b01816 Crew, 2018, Identification and characterization of von hippel-lindau-recruiting proteolysis targeting chimeras (PROTACs) of TANK-binding kinase 1, J. Med. Chem., 61, 583, 10.1021/acs.jmedchem.7b00635 Kelm, 2023, PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy, Mol. Cancer, 22, 62, 10.1186/s12943-022-01707-5 Buckley, 2015, HaloPROTACS: Use of small molecule PROTACs to induce degradation of HaloTag fusion proteins, ACS Chem. Biol., 10, 1831, 10.1021/acschembio.5b00442 Bondeson, 2018, Lessons in PROTAC design from selective degradation with a promiscuous warhead, Cell Chem. Biol., 25, 78, 10.1016/j.chembiol.2017.09.010 Lai, 2016, Modular PROTAC design for the degradation of oncogenic BCR-ABL, Angew. Chem. Int. Ed Engl., 55, 807, 10.1002/anie.201507634 Donovan, 2020, Mapping the degradable kinome provides a resource for expedited degrader development, Cell, 183, 1714, 10.1016/j.cell.2020.10.038 Troup, 2020, Current strategies for the design of PROTAC linkers: A critical review, Explor. Target. Anti Tumor Ther., 1, 273 Huang, 2018, A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader, Cell Chem. Biol., 25, 88, 10.1016/j.chembiol.2017.10.005 Qin, 2018, Discovery of QCA570 as an exceptionally potent and efficacious proteolysis targeting Chimera (PROTAC) degrader of the bromodomain and extra-terminal (BET) proteins capable of inducing complete and durable tumor regression, J. Med. Chem., 61, 6685, 10.1021/acs.jmedchem.8b00506 Lebraud, 2016, Protein degradation by In-cell self-assembly of proteolysis targeting chimeras, ACS Cent. Sci., 2, 927, 10.1021/acscentsci.6b00280 Remillard, 2017, Degradation of the BAF complex factor BRD9 by heterobifunctional ligands, Angew. Chem. Int. Ed., 56, 5738, 10.1002/anie.201611281 Nowak, 2018, Plasticity in binding confers selectivity in ligand-induced protein degradation, Nat. Chem. Biol., 14, 706, 10.1038/s41589-018-0055-y Kaelin, 2005, The von hippel-lindau tumor suppressor protein: Roles in cancer and oxygen sensing, Cold Spring Harb. Symp. Quant. Biol., 70, 159, 10.1101/sqb.2005.70.001 Shi, 2017, Cereblon: A protein crucial to the multiple functions of immunomodulatory drugs as well as cell metabolism and disease generation, J. Immunol. Res., 2017, 1, 10.1155/2017/5476903 Silke, 2013, Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation, Cold Spring Harb. Perspect. Biol., 5, 1, 10.1101/cshperspect.a008730 Zhang, 2019, Acquired resistance to BET-PROTACs (proteolysis-targeting chimeras) caused by genomic alterations in core components of E3 ligase complexes, Mol. Cancer Ther., 18, 1302, 10.1158/1535-7163.MCT-18-1129 Powell, 2018, Chemically induced degradation of anaplastic lymphoma kinase (ALK), J. Med. Chem., 61, 4249, 10.1021/acs.jmedchem.7b01655 Han, 2019, Discovery of ARD-69 as a highly potent proteolysis targeting Chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer, J. Med. Chem., 62, 941, 10.1021/acs.jmedchem.8b01631 Han, 2019, Discovery of highly potent and efficient PROTAC degraders of androgen receptor (AR) by employing weak binding affinity VHL E3 ligase ligands, J. Med. Chem., 62, 11218, 10.1021/acs.jmedchem.9b01393 Neklesa, 2018, ARV-110: An androgen receptor PROTAC degrader for prostate cancer, Cancer Res, 78, 5236, 10.1158/1538-7445.AM2018-5236 Neklesa, 2019, ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer, J. Clinl. Onco., 37, 1200 Khan, 2019, A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity, Nat. Med., 25, 1938, 10.1038/s41591-019-0668-z Burslem, 2019, Targeting BCR-ABL1 in chronic myeloid leukemia by PROTACS-mediated targeted protein degradation, Cancer. Res., 79, 4744, 10.1158/0008-5472.CAN-19-1236 Zhao, 2019, Discovery of SIAIS178 as an effective BCR-ABL degrader by recruiting von hippel–lindau (VHL) E3 ubiquitin ligase, J. Med. Chem., 62, 9281, 10.1021/acs.jmedchem.9b01264 Lim, 2019, Proteolysis targeting chimeric molecules as therapy for multiple myeloma: Efficacy, biomarker and drug combinations, Haematologica, 104, 1209, 10.3324/haematol.2018.201483 Roy, 2019, SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate, ACS Chem. Biol., 14, 361, 10.1021/acschembio.9b00092 Buhimschi, 2018, Targeting the C481S ibrutinib-resistance mutation in Bruton’s tyrosine kinase using PROTAC-mediated degradation, Biochemistry, 57, 3564, 10.1021/acs.biochem.8b00391 Jaime-Figueroa, 2020, Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties, Bioorg. Med. Chem. Lett., 30, 126877, 10.1016/j.bmcl.2019.126877 Zhao, 2019, PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer, Chem. Commun., 55, 2704, 10.1039/C9CC00163H Chen, 2018, Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin-proteasome pathway, Bioorg. Chem., 81, 536, 10.1016/j.bioorg.2018.09.005 Wu, 2019, Development of multifunctional histone deacetylase 6 degraders with potent antimyeloma activity, J. Med. Chem., 62, 7042, 10.1021/acs.jmedchem.9b00516 Li, 2019, Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting Chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression, J. Med. Chem., 62, 448, 10.1021/acs.jmedchem.8b00909 Zhou, 2019, Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein, J. Med. Chem., 62, 11280, 10.1021/acs.jmedchem.9b01530 Hu, 2019, Discovery of ERD-308 as a highly potent proteolysis targeting Chimera (PROTAC) degrader of estrogen receptor (ER), J. Med. Chem., 62, 1420, 10.1021/acs.jmedchem.8b01572 Li, 2018, Phthalimide conjugations for the degradation of oncogenic PI3K, Eur. J. Med. Chem., 151, 237, 10.1016/j.ejmech.2018.03.066 Cyrus, 2011, Impact of linker length on the activity of PROTACs, Mol. BioSyst., 7, 359, 10.1039/C0MB00074D Burslem, 2017, Small-molecule modulation of protein homeostasis, Chem. Rev., 117, 11269, 10.1021/acs.chemrev.7b00077 Cecchini, 2022, Linkers as game-changers in PROTAC technology: Emphasizing general trends in PROTAC pharmacokinetics for their rational design, CHIMIA, 76, 341, 10.2533/chimia.2022.341 Churcher, 2018, Protac-induced protein degradation in drug discovery: Breaking the rules or just making new ones?, J. Med. Chem., 61, 444, 10.1021/acs.jmedchem.7b01272 Wang, 2020, Degradation of proteins by PROTACs and other strategies, Acta Pharm. Sin. B, 10, 207, 10.1016/j.apsb.2019.08.001 Atilaw, 2021, Solution conformations shed light on PROTAC cell permeability, ACS Med. Chem. Lett., 12, 107, 10.1021/acsmedchemlett.0c00556 Webster, 2007, PEGylated proteins: Evaluation of their safety in the absence of definitive metabolism studies, Drug Metab. Dispos., 35, 9, 10.1124/dmd.106.012419 Baumann, 2014, Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: Quo vadis?, Drug Discov. Today, 19, 1623, 10.1016/j.drudis.2014.06.002 R. Webster, V. Elliott, B.K. Park, et al., PEG and PEG conjugates toxicity: Towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals. PEGylated Protein Drugs: Basic Science and Clinical Applications., 2009: 127-146. Cecchini, 2021, From conception to development: Investigating PROTACs features for improved cell permeability and successful protein degradation, Front. Chem., 9, 672267, 10.3389/fchem.2021.672267 Klein, 2020, Understanding and improving the membrane permeability of VH032-based PROTACs, ACS Med. Chem. Lett., 11, 1732, 10.1021/acsmedchemlett.0c00265 Sun, 2019, PROTACs: Great opportunities for academia and industry, Signal Transduct, Target. Ther., 4, 64 Lee, 2007, Targeted degradation of the aryl hydrocarbon receptor by the PROTAC approach: A useful chemical genetic tool, ChemBioChem, 8, 2058, 10.1002/cbic.200700438 Burslem, 2018, The advantages of targeted protein degradation over inhibition: An RTK case study, Cell Chem. Biol., 25, 67, 10.1016/j.chembiol.2017.09.009 Lu, 2015, Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4, Chem. Biol., 22, 755, 10.1016/j.chembiol.2015.05.009 Honigberg, 2010, The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy, Proc. Natl. Acad. Sci. U. S. A., 107, 13075, 10.1073/pnas.1004594107 Gabizon, 2020, Efficient targeted degradation via reversible and irreversible covalent PROTACs, J. Am. Chem. Soc., 142, 11734, 10.1021/jacs.9b13907 Cromm, 2017, Targeted protein degradation: From chemical biology to drug discovery, Cell Chem. Biol., 24, 1181, 10.1016/j.chembiol.2017.05.024 Wang, 2023, PROTACS: A technology with a gold rush-like atmosphere, Eur. J. Med. Chem., 247, 115037, 10.1016/j.ejmech.2022.115037 Paiva, 2019, Targeted protein degradation: Elements of PROTAC design, Curr. Opin. Chem. Biol., 50, 111, 10.1016/j.cbpa.2019.02.022 Flanagan, 2019, Targeting nuclear receptors with PROTAC degraders, Mol. Cell. Endocrinol., 493, 110452, 10.1016/j.mce.2019.110452 Wang, 2021, PROTACs technology for targeting non-oncoproteins: Advances and perspectives, Bioorg. Chem., 114, 105109, 10.1016/j.bioorg.2021.105109 Jellinger, 2008, Neuropathological aspects of alzheimer disease, parkinson disease and frontotemporal dementia, Neurodegener. Dis., 5, 118, 10.1159/000113679 Garber, 2022, The PROTAC gold rush, Nat. Biotechnol., 40, 12, 10.1038/s41587-021-01173-2 Mullard, 2021, Targeted protein degraders crowd into the clinic, Nat. Rev. Drug Discov., 20, 247, 10.1038/d41573-021-00052-4 Bondeson, 2015, Catalytic in vivo protein knockdown by small-molecule PROTACs, Nat. Chem. Biol., 11, 611, 10.1038/nchembio.1858 Kang, 2018, Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC), Biochem. Biophys. Res. Commun., 505, 542, 10.1016/j.bbrc.2018.09.169 Crew, 2020, Modulators of estrogen receptor proteolysis and associated methods of use, United States patent 10,604,506 Ariazi, 2006, Estrogen receptors as therapeutic targets in breast cancer, Curr. Top. Med. Chem., 6, 181, 10.2174/156802606776173483 Rodriguez-Gonzalez, 2008, Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer, Oncogene, 27, 7201, 10.1038/onc.2008.320 Flanagan, 2019, Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer, Cancer Res, 79, P5, 10.1158/1538-7445.SABCS18-P5-04-18 Samarasinghe, 2021, Targeted protein degradation: A promise for undruggable proteins, Cell Chem. Biol., 28, 934, 10.1016/j.chembiol.2021.04.011 Békés, 2022, PROTAC targeted protein degraders: The past is prologue, Nat. Rev. Drug Discov., 21, 181, 10.1038/s41573-021-00371-6 Burke, 2022, Overcoming cancer drug resistance utilizing PROTAC technology, Front. Cell Dev. Biol., 10, 872729, 10.3389/fcell.2022.872729 Ciechanover, 2000, Ubiquitin-mediated proteolysis: Biological regulation via destruction, BioEssays, 22, 442, 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q Lai, 2017, Induced protein degradation: An emerging drug discovery paradigm, Nat. Rev. Drug Discov., 16, 101, 10.1038/nrd.2016.211 Mayor-Ruiz, 2019, Plasticity of the cullin-RING ligase repertoire shapes sensitivity to ligand-induced protein degradation, Mol. Cell, 75, 849, 10.1016/j.molcel.2019.07.013 Ottis, 2019, Cellular resistance mechanisms to targeted protein degradation converge toward impairment of the engaged ubiquitin transfer pathway, ACS Chem. Biol., 2215 Shirasaki, 2021, Functional genomics identify distinct and overlapping genes mediating resistance to different classes of heterobifunctional degraders of oncoproteins, Cell Rep, 34, 108532, 10.1016/j.celrep.2020.108532 Barrio, 2020, IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma, Haematologica, 105, 237, 10.3324/haematol.2019.217943 Gooding, 2021, Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma, Blood, 137, 232, 10.1182/blood.2020007081 Van Nguyen, 2021, USP15 antagonizes CRL4CRBN-mediated ubiquitylation of glutamine synthetase and neosubstrates, Proc. Natl. Acad. Sci. U. S. A., 118, 1 Oh, 2018, Principles of ubiquitin-dependent signaling, Annu. Rev. Cell Dev. Biol., 34, 137, 10.1146/annurev-cellbio-100617-062802 Schapira, 2019, Targeted protein degradation: Expanding the toolbox, Nat. Rev. Drug Discov., 18, 949, 10.1038/s41573-019-0047-y Pacini, 2021, Integrated cross-study datasets of genetic dependencies in cancer, Nat. Commun., 12, 1661, 10.1038/s41467-021-21898-7 Zimmerman, 2010, Structural assembly of cullin-RING ubiquitin ligase complexes, Curr. Opin. Struct. Biol., 20, 714, 10.1016/j.sbi.2010.08.010 Duda, 2011, Structural regulation of cullin-RING ubiquitin ligase complexes, Curr. Opin. Struct. Biol., 21, 257, 10.1016/j.sbi.2011.01.003 Baek, 2020, NEDD8 nucleates a multivalent cullin-RING-UBE2D ubiquitin ligation assembly, Nature, 578, 461, 10.1038/s41586-020-2000-y Baek, 2021, NEDD8 and ubiquitin ligation by cullin-RING E3 ligases, Curr. Opin. Struct. Biol., 67, 101, 10.1016/j.sbi.2020.10.007 Hines, 2019, MDM2-recruiting PROTAC offers superior, synergistic antiproliferative activity via simultaneous degradation of BRD4 and stabilization of p53, Cancer Res, 79, 251, 10.1158/0008-5472.CAN-18-2918 Itoh, 2010, Protein knockdown using methyl bestatin–ligand hybrid molecules: Design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins, J. Am. Chem. Soc., 132, 5820, 10.1021/ja100691p Liu, 2020, PROTACs: A novel strategy for cancer therapy, Semin. Cancer Biol., 67, 171, 10.1016/j.semcancer.2020.02.006 Snyder Lawrence, 2021, The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer, Cancer Res, 81, 44, 10.1158/1538-7445.AM2021-44 Suzuki, 2013, Toward clinical application of the Keap1-Nrf2 pathway, Trends Pharmacol. Sci., 34, 340, 10.1016/j.tips.2013.04.005 Jaramillo, 2013, The emerging role of the Nrf2-Keap1 signaling pathway in cancer, Genes Dev, 27, 2179, 10.1101/gad.225680.113 Lu, 2016, The Keap1-Nrf2-ARE pathway As a potential preventive and therapeutic target: An update, Med. Res. Rev., 36, 924, 10.1002/med.21396 Lu, 2018, Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway, Eur. J. Med. Chem., 146, 251, 10.1016/j.ejmech.2018.01.063 Xiao, 2022, Recent advances of degradation technologies based on PROTAC mechanism, Biomolecules, 12, 1257, 10.3390/biom12091257 Moon, 2018, Chemically induced cellular proteolysis: An emerging therapeutic strategy for undruggable targets, Mol. Cells, 41, 933 Tse, 2008, ABT-263: A potent and orally bioavailable bcl-2 family inhibitor, Cancer Res, 68, 3421, 10.1158/0008-5472.CAN-07-5836 Park, 2008, Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins, J. Med. Chem., 51, 6902, 10.1021/jm800669s Zhang, 2020, Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity, Eur. J. Med. Chem., 192, 112186, 10.1016/j.ejmech.2020.112186 Mason, 2007, Programmed anuclear cell death delimits platelet life span, Cell, 128, 1173, 10.1016/j.cell.2007.01.037 Zhang, 2022, The PROTAC selectively degrading Bcl-xL represents a novel Hedgehog pathway inhibitor with capacity of combating resistance to Smoothened inhibitors while sparing bone growth, Theranostics, 12, 7476, 10.7150/thno.75421 Sawa, 2007, Protein S-guanylation by the biological signal 8-nitroguanosine 3’, 5’-cyclic monophosphate, Nat. Chem. Biol., 3, 727, 10.1038/nchembio.2007.33 Takahashi, 2019, AUTACs: Cargo-specific degraders using selective autophagy, Mol. Cell, 76, 797, 10.1016/j.molcel.2019.09.009 Lamark, 2017, Regulation of selective autophagy: The p62/SQSTM1 paradigm, Essays Biochem, 61, 609, 10.1042/EBC20170035 Stolz, 2014, Cargo recognition and trafficking in selective autophagy, Nat. Cell Biol., 16, 495, 10.1038/ncb2979 Chun, 2005, Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model, Int. J. Cancer, 114, 124, 10.1002/ijc.20687 Romano, 2010, FK506 binding proteins as targets in anticancer therapy, Anti Cancer Agents Med. Chem., 10, 651, 10.2174/187152010794479816 Winter, 2015, Phthalimide conjugation as a strategy for in vivo target protein degradation, Science, 348, 1376, 10.1126/science.aab1433 VanDyke, 2022, Biologics-based degraders—An expanding toolkit for targeted-protein degradation, Curr. Opin. Biotechnol., 78, 102807, 10.1016/j.copbio.2022.102807 Banik, 2020, Lysosome-targeting chimaeras for degradation of extracellular proteins, Nature, 584, 291, 10.1038/s41586-020-2545-9 Ahn, 2021, LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation, Nat. Chem. Biol., 17, 937, 10.1038/s41589-021-00770-1 Zhao, 2022, Targeted protein degradation: Mechanisms, strategies and application, Signal Transduct. Target. Ther., 7, 113, 10.1038/s41392-022-00966-4 Ding, 2020, Emerging new concepts of degrader technologies, Trends Pharmacol. Sci., 41, 464, 10.1016/j.tips.2020.04.005 Van Regenmortel, 2001, Antigenicity and immunogenicity of synthetic peptides, Biologicals, 29, 209, 10.1006/biol.2001.0308 Ramadas, 2021, An emerging tool for the degradation of non-cytosolic proteins, ChemMedChem, 16, 2951, 10.1002/cmdc.202100393 Cotton, 2021, Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1, J. Am. Chem. Soc., 143, 593, 10.1021/jacs.0c10008 Zebisch, 2013, Structural and molecular basis of ZNRF3/RNF43 transmembrane ubiquitin ligase inhibition by the Wnt agonist R-spondin, Nat. Commun., 4, 2787, 10.1038/ncomms3787 Beck, 2017, Strategies and challenges for the next generation of antibody-drug conjugates, Nat. Rev. Drug Discov., 16, 315, 10.1038/nrd.2016.268 Zhang, 2021, Covalently engineered nanobody chimeras for targeted membrane protein degradation, J. Am. Chem. Soc., 143, 16377, 10.1021/jacs.1c08521 Verdurmen, 2017, A quantitative comparison of cytosolic delivery via different protein uptake systems, Sci. Rep., 7, 13194, 10.1038/s41598-017-13469-y Han, 2020, Protein labeling approach to improve lysosomal targeting and efficacy of antibody–drug conjugates, Org. Biomol. Chem., 18, 3229, 10.1039/D0OB00265H Fang, 2018, Nanobody immunostaining for correlated light and electron microscopy with preservation of ultrastructure, Nat. Meth., 15, 1029, 10.1038/s41592-018-0177-x Rana, 2021, Inhibitors, PROTACs and molecular glues as diverse therapeutic modalities to target cyclin-dependent kinase, Cancers, 13, 5506, 10.3390/cancers13215506 Nalawansha, 2020, PROTACs: An emerging therapeutic modality in precision medicine, Cell Chem. Biol., 27, 998, 10.1016/j.chembiol.2020.07.020 Tian, 2021, PROTAC compatibilities, degrading cell-surface receptors, and the sticky problem of finding a molecular glue, ChemMedChem, 16, 316, 10.1002/cmdc.202000683 Story, 1994, A major histocompatibility complex class I-like Fc receptor cloned from human placenta: Possible role in transfer of immunoglobulin G from mother to fetus, J. Exp. Med., 180, 2377, 10.1084/jem.180.6.2377 West, 2000, Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,), Biochemistry, 39, 9698, 10.1021/bi000749m Lambert, 2018, The human transcription factors, Cell, 172, 650, 10.1016/j.cell.2018.01.029 Lambert, 2018, Targeting transcription factors for cancer treatment, Molecules, 23, 1479, 10.3390/molecules23061479 Samarasinghe, 2021, Targeted degradation of transcription factors by TRAFTACs: TRAnscription Factor TArgeting Chimeras, Cell Chem. Biol., 28, 648, 10.1016/j.chembiol.2021.03.011 Wang, 2022, Nucleic-acid-based targeted degradation in drug discovery, J. Med. Chem., 65, 10217, 10.1021/acs.jmedchem.2c00875 Hu, 2022, Recent developments in PROTAC-mediated protein degradation: From bench to clinic, ChemBioChem, 23, 10.1002/cbic.202100270 Fang, 2022, Progress and challenges in targeted protein degradation for neurodegenerative disease therapy, J. Med. Chem., 65, 11454, 10.1021/acs.jmedchem.2c00844 Li, 2021, Therapeutic targeting of RNA-binding protein by RNA-PROTAC, Mol. Ther., 29, 1940, 10.1016/j.ymthe.2021.04.032 Ghidini, 2021, RNA-PROTACs: Degraders of RNA-binding proteins, Angew. Chem., 133, 3200, 10.1002/ange.202012330 Liu, 2021, TF-PROTACs enable targeted degradation of transcription factors, J. Am. Chem. Soc., 143, 8902, 10.1021/jacs.1c03852 Zhu, 2023, Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance, Pharmacol. Ther., 244, 108371, 10.1016/j.pharmthera.2023.108371 Moon, 2023, Cancer-specific delivery of proteolysis-targeting chimeras (PROTACs) and their application to cancer immunotherapy, Pharmaceutics, 15, 411, 10.3390/pharmaceutics15020411 He, 2021, Aptamer-PROTAC conjugates (APCs) for tumor-specific targeting in breast cancer, Angew. Chem., 133, 23487, 10.1002/ange.202107347 Liu, 2022, Cooperatively designed aptamer-PROTACs for spatioselective degradation of nucleocytoplasmic shuttling protein for enhanced combinational therapy, bioRxiv Fan, 2023, Application of aptamer-drug delivery system in the therapy of breast cancer, Biomed, Pharmacother, 161, 114444, 10.1016/j.biopha.2023.114444 Khan, 2020, PROteolysis TArgeting chimeras (PROTACs) as emerging anticancer therapeutics, Oncogene, 39, 4909, 10.1038/s41388-020-1336-y Verma, 2020, Controlling PROTACs with light, ChemMedChem, 15, 1258, 10.1002/cmdc.202000249 Xue, 2019, Light-induced protein degradation with photocaged PROTACs, J. Am. Chem. Soc., 141, 18370, 10.1021/jacs.9b06422 Pfaff, 2019, Reversible spatiotemporal control of induced protein degradation by bistable PhotoPROTACs, ACS Cent. Sci., 5, 1682, 10.1021/acscentsci.9b00713 Liu, 2021, Light-controllable PROTACs for temporospatial control of protein degradation, Front. Cell Dev. Biol., 9, 678077, 10.3389/fcell.2021.678077 Stupar, 2010, Into the wild: The soybean genome meets its undomesticated relative, Proc. Natl. Acad. Sci. U. S. A., 107, 21947, 10.1073/pnas.1016809108 Cadet, 2011, Oxidatively generated damage to DNA by UVA radiation in cells and human skin, J. Investig. Dermatol., 131, 1005, 10.1038/jid.2011.51 Zhao, 2022, Novel design strategies to enhance the efficiency of proteolysis targeting chimeras, ACS Pharmacol. Transl. Sci., 5, 710, 10.1021/acsptsci.2c00089 Liu, 2021, Cancer selective target degradation by folate-caged PROTACs, J. Am. Chem. Soc., 143, 7380, 10.1021/jacs.1c00451 Yang, 2023, Recent advances in targeted protein degraders as potential therapeutic agents, Mol. Divers., 1 Tomoshige, 2021, In vivo synthetic chemistry of proteolysis targeting chimeras (PROTACs), Bioorg. Med. Chem., 41, 116221, 10.1016/j.bmc.2021.116221